Adaptimmune

  • Home
  • Our Company
    • Overview arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
  • Products
  • Pipeline
    • Overview arrow_forward
    • Afami-cel arrow_forward
    • Lete-cel arrow_forward
    • Uza-cel arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Videos arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media Resources
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • General Meeting (merger)
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • News Center

  • Media Resources
  • Corporate Presentations
  • Press Releases
  • Publications
  • Events
  • Email Alerts
Dec 05, 2017 5:00pm EST

Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study

Nov 10, 2017 8:58am EST

Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 09, 2017 8:00am EST

NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy

Nov 06, 2017 8:09am EST

Adaptimmune marks Official Opening of U.K. Headquarters

Nov 03, 2017 2:22pm EDT

Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 03, 2017 2:17pm EDT

Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting

Nov 02, 2017 7:30am EDT

Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates

Oct 27, 2017 11:11am EDT

Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017

Oct 23, 2017 5:51pm EDT

Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations

Sep 22, 2017 10:00am EDT

James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

RSS
  • Prev
  • 1...
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • ...29
  • Next
Adaptimmune
Disclosures Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2025 Adaptimmune. All Rights Reserved.